{'fraction_non_alphanumeric': 0.02252252252252252, 'fraction_numerical': 0.0, 'mean_word_length': 4.985029940119761, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Biologics Provide Hope For Immune System Disorders: Patients tell the story and ask for appropriate access.

Every year, innovations come to market that can provide substantial relief to patients with serious chronic conditions. As they do, managed care professionals grapple with hard decisions about triaging conditions, establishing which treatments to include in formularies, and defining the circumstances under which a patient should be covered. 
 
In the documentary film INNER-STATE, three people with three kinds of immune-mediated inflammatory disorders — Crohn’s disease, rheumatoid arthritis (RA), and psoriasis — give a broader perspective into the many different factors that go into a treatment decision. They bring the statistics to life by sharing their journeys from onset to diagnosis to treatment, through years of debilitating illness and struggle. In each story, the far-reaching impact of these conditions is a common thread. The people who are featured in the film suffer from several related physical and psychological injuries, while their families deal with substantial emotional and economic strain. Communities are robbed of these patients’ valuable contributions to schools, organizations, and the workforce. 
 
 
 
 
 
 
 
A poster for the documentary film INNERSTATE. 
 
 
 
Centocor, with support from groups like the National Psoriasis Foundation, has been screening the film across the country to help educate patients, their families, and the general public. Another group stands to benefit from being in the audience as well: managed care professionals. By watching patient stories unfold in such detail — the debilitating long-term impact, the related conditions and stresses, the struggles to get coverage and access to treatment — payers can learn more about conditions for which they may have limited familiarity. This may lead to a better understanding of how to identify appropriate individuals for treatment and which biologics to include on formularies.